Breast Cancer is the most common type of cancer which attacks women in the late adulthood stage and as the years go by, the number of victims of breast cancer also continues to grow bigger. But there is already hope presented when another study came out last Wednesday. According to the latest study about how to survive from breast cancer, it was revealed that postmenopausal women with a common type of breast cancer that thrives on estrogen has survived longer when treated with a combination of two drugs rather than just one.

Some say that this is not effective especially when some drugs are said to be counteracting the effects of the other drug. The results of the phase III trial, released at a meeting of breast cancer experts in San Antonio, Texas, show that the first benefit for women with hormone receptor-positive metastatic breast cancer in 10 years. This was according to the authors that conducted the new study.

The drugs which were tested in this study were Anastrazole (Arimidex) and fulvestrant (Faslodex). Both drugs are currently used to treat breast cancer but they have typically been administered separately. Meaning, they can’t be given together.

The study was started in the year 2004 and there were about 707 participants, all are postmenopausal women with metastatic hormone receptor-positive breast cancer. The results revealed that when the two drugs were used together to treat breast cancer, they extend the median survival time by more than six months compared to the standard treatment with only using anastrazole.